Interleukin (IL) 4 is a multifunctional T cell-derived cytokine that inhibits cytokine production and certain effector functions in human monocytes, while enhancing others. We show that II:4 may contribute to the downregulation and resolution of an inflammatory response by selectively promoting expression of the IL-1 receptor antagonist (IL-lra) that blocks the action of IL-1. IL-lra specifically binds to the II.-1 receptor without initiating signal transduction. Peripheral blood monocytes obtained from cancer patients, before and immediately after a regimen of II-4 immunotherapy, were examined for IL-lra gene expression. After II.-4 therapy, monocytes from the patients showed a marked increase in Iblra mRNA. This selective induction of Iblra mRNA in circulating monocytes was reflected by significantly enhanced serum levels of Iblra (p <0.01) during II-4 therapy, which declined after II.-4 treatment. In vitro analysis of II-4 regulation of monocytes from normal individuals revealed a dose-dependent induction of II.-lra mRNA within 2-4 h after stimulation without a concomitant effect on the expression of Ibl mRNA. Increased IL-lra mRNA was not due to RNA stabilization, but occurred at the level of transcription. In the presence of LPS, IL-4 not only augmented Iblra levels, but markedly inhibited LPS-induced II.-1 mRNA expression. The selective upregulation of IL-lra by resting or activated monocytes, coupled with inhibition of II-1 production by activated monocytes, as we demonstrate both in vitro and in vivo, suggests that II.-4 may prove clinically useful as a systemic antiinflammatory agent.
T
he balance between immune responses to infectious agents and antigens and the development of immune-mediated host injury depends, to a large extent, on the elicitation and actions of soluble immunoregulatory cytokines. Cytokines such as Ib2 and IFN-% which promote the development of cell-mediated immunity, are derived from Thl helper T lymphocytes, whereas Th2 cells promote primarily B cell development and function through the production of Ib4, -5, -6, and -10 (for review, see reference 1). Although originally characterized in mice, Thl and Th2 subsets have recently been identified in humans through the isolation of CD4 + clones from patients with different pathologic profiles (2, 3) . Emerging evidence suggests that in addition to regulating the humoral immune response (4, 5) , cytokines secreted by Th2 ceUs may also function to suppress call-mediated immune pathways normally potentiated by Thl-derived cytokines. For example, II:4 has been shown to inhibit the production of monokines (6) (7) (8) , PGE2, and metalloproteinases induced by IFN-~/and other stimuli (6, 7, (9) (10) (11) , and by inhibiting the expression of Fear (12, D), IL-4 may limit phagocytosis and the release of reactive oxygen intermediates. These in vitro observations of an antiinflammatory role for IL-4 have recently been extended in studies in vivo. Patients participating in a clinical trial using Ib4 as an anticancer agent displayed altered monocyte functions in which posttherapy monocytes exhibited a significantly diminished ability to secrete PGE2 and superoxide anion (7) . After isolation of the monocytes from the patients receiving IL4 therapy, the cells recovered their ability to generate IL-1 when challenged in vitro with LPS (7) . However, based on recent evidence that Ib4 induces the II:1 receptor antagonist (Iblra) 1 in a monocytic cell line (14) , and augments ILlra production in LPS-stimulated blood monocytes (15, 16) , we subsequently evaluated patient monocytes for II~lra gene expression before and after IL-4 therapy. IL-lra, a 22-25-kD glycosylated protein (17, 18) , binds to the human type I and type II Ibl receptors with similar affinity as ID1B and IL-lc~, but does not initiate internalization of the receptor-ligand complex or transduce an activation signal (19) . After systemic I1-4 therapy, we found that monocytes from the patients expressed increased mRNA for I1-1ra that was reflected by a 10-fold increase in serum I1.1ra levels. Characterization of the mechanism by which I1-4 regulates I1-1ra mRNA production and peptide secretion revealed rapid and transient induction that was dependent on increased transcription. These data, together with the ability of I1.4 to suppress inducible I1.1 synthesis, implicate IL-4 as a unique systemic antiinflammatory agent.
Materials and Methods
Monocyte Isolation and Culture. PBMC were obtained by leukapheresis (National Institutes of Health Department of Transfusion Medicine) with subsequent centrifugation of the cells through Ficoll-Hypaque (7). Monocyte populations were then purified (90-95% CD14 +) by counterflow centrifugal elutriation (20) . Monocytes were resuspended in DMEM (Cellgro/Mediatech, Washington, DC) supplemented with 50/~g/ml gentamicin sulfate (Whittaker Bioproducts, Walkersville, MD) and 2 mM L-glutamine (Gibco, Grand Island, NY) and cultured in suspension in 17 x 100-ram polypropylene tubes (Falcon/Becton Dickinson Labware, Lincoln Park, NJ) or as adherent monohyers in 24-weU plates (Costar Corp., Cambridge, MA) (106/ml) in the absence or presence of recombinant human Ib4 (Genzyme Corp., Cambridge, MA and Immunex Corp., Seattle, WA) which by limulus assay contained <0.06 EU/ml (1 EU = 0.1 ng/ml endotoxin, the limit of detection of the assay; courtesy of Dr. D. Hochstein, Federal Drug Administration, Bethesda, MD). Cultures were then stimulated or not with LPS (LPS, Escherichia coli 055.B5, Difco Laboratories, Inc., Detroit, MI) for the indicated time periods.
Patient Populations. Patients with renal cell carcinoma or with malignant mdanoma were given rlL-4 (generously provided by Dr. S. Gillis, Immunex Corp., and Dr. E. Bradley, Sterling Pharmaceutical, Malvern, PA; sp act 1.5 x 107 U/rag) at doses ranging from 10 to 20 I~g/kg body weight three times daily for 3-5 d (7). One day before initiation, during, and at indicated intervals after 11.,4 immunotherapy, patients were leukapheresed and the monocytes were purified by elutriation. Monocytes were processed immediately or cryopreserved after isolation enabling pre-and posttherapy cells to be thawed and analyzed simultaneously (7) . AU patients were treated according to National Cancer Institute Institutional Review Board approved protocols and signed informed consent before treatment.
Northern Blot Analysis. Monocytes were cultured in suspension (10Vml in 17 x 100-mm tubes) with or without IL-4, washed with PBS, and total cellular RNA was isolated by using a one-step acid guanidinium-thiocyanate-phenol-chloroform procedure (21) . RNA samples (5 #g) were electrophoresed in 1% formaldehyde-agarose gels, blotted onto nitrocellulose filters (Schleicher & Schuell, Inc., Keene, NH) and prehybridized at 42~ for at least 4 h before hybridization at 42~ with 32p-labeled human Ibl~ (22) , IL-lra (18), (generously provided by Dr. D. Carter, UpJohn Co., Kalamazoo, MI), He7, or glyceraldehyde 3-phosphate dehydrogenase (GAFDH) (23) eDNA probes. The blots were washed twice in 2x SSC, 0.1% SDS for 15 min at 22~ and once in 0.1x SSC, 0.1% SDS for 30 rain at 65~ After washing, the filters were exposed to a phosphor screen (Molecular Dynamics, Sunnyvale, CA) for 1-24 h. Scanned images were obtained using a Phospliorlmager and Image Quant software (Molecular Dynamics), transferred and reproduced using Macintosh Adobe Photoshop, Image and Aldus pagemaker (Apple Computer, Inc., Cupertino, CA) software and printed on a color printer (Phaser CP; Tektronix, Inc., Beaverton, OR).
Nuclear Run-offAssays. Monocytes (5 x 107) were cultured in the presence or absence of lb4 (1,000 U/ml) and nuclei were isolated by lysis of the cells in 10 mM Tris-HC1, pH 7.5, 2 mM MgC12, 3 mM CaCI2, 3 k~M DTT, 0.3 M sucrose and 0.5% Triton X-100 and disruption with a Dounce homogenizer (size B; Wheaton Scientific, Millville, NJ). The disrupted cells were then centrifuged at 3000 g for 10 min at 4~ through a cushion of 30% sucrose and 0.5% Triton X-100 to pellet the nuclei. For the runoff assay, 100/~1 of reaction buffer (10 mM Tris-HC1, pH 8.0, 5 mM MgC12, 0.3 M KC1 and 5/~M DTT) with 100 mM ATP, CTP, and GTP, and 100/~Ci ot-[32p] UTP (>760 Ci/mmole, Amersham Corp., Arlington Heights, IL) was added to each sample of nuclei. After incubation with continuous shaking at 30~ for 30 min, nuclear transcripts were purified (21) and hybridized at 62~ for 36 h to nitrocellulose filters on which 5/zg oflinearized, denatured plasmid DNA had been immobilized. The filters were then washed twice for 30 rain in 2x SSC, 0.1% SDS at 62~ treated with IkNase A (10/zg/ml) in 2x SSC for 30 rain at 37~ and washed with 2x SSC, 0.1% SDS for 30 min at 37~ The filters were exposed to a phosphor screen for 3-16 h and phosphorimages were scanned.
IL.lra ELISA. IL-lra peptide was detected using an ELISA kit purchased from R&D Systems, Inc. (Minneapolis, MN).
Results

IL, lra Is Increased in Cancer Patients Receiving vii.,4 Immunotheralr/.
As part of a treatment protocol, recombinant human I1.4 was administered intravenously to cancer patients three times daily for 3-5 d. PBMC were obtained 1 d before I1.4 and immediately after cessation of I1.4 administration. After elutriation of the PBMC, the monocytes (>90% CD14 4) were cultured and RNA was isolated for Northern analysis with the II-1 and I1.1ra cDNA probes. Although low levels of I1.1ra mRNA were sometimes detectable in monocytes from the cancer patients before therapy as represented in Fig. 1 , a substantial increase in IL-lra gene expression was observed in most patients after Ib4 therapy. In contrast, when the same mRNA was probed for I1.1/3, little or no Ibl/3 mlLNA was detected before or after Ib4 therapy (Fig. 1) . Thus, exposure of circulating monocytes to Ib4 in vivo results in a selective augmentation of gene expression for I1.1ra without a concomitant increase in II-1/3 mRNA.
To determine if there was a corresponding increase in I1-lra protein in these patients, serum samples were collected before, during, and 3-12 wk after I1-4 therapy. These serial samples provided internal controls for each patient. Using an I1-1ra-specific ELISA, a striking increase in I1-1ra protein was measured in the serum of the majority of patients during the course of I1-4 therapy (Fig. 2) . Whereas pretherapy levels for I1-1ra were only 1.3 _+ 0.23 ng/ml, the levels increased 10-fold during therapy (13.54 _+ 3.29; n = 7; p <0.01). The increase in serum I1-1ra was transient, since serum collected from the same patients 3-12 wk after therapy contained I1-lra at or near pretherapy levels (1.9 +_ 0.67 ng/ml). In those patients whose serum and monocyte mRNA were both available for evaluation, a correlation existed between these two parameters. Patients with increased I1-1ra mRNA also expressed high serum I1-1ra levels (patients 1, 2, 3, and 5 in were isolated from six of these patients before (-) and within 24 h after (+) Ib4 treatment, cultured, and total cellular RNA isolated for Northern analysis with the Iblra and IF1 cDNA probes. RNA was monitored by ethidium bromide staining of the 18s and 28s ribosomal RNA bands to determine equivalent loading of RNA in each lane. Fig. 1 had 27 .52, 7.03, 5.65, and 20.46 ng/ml serum I1:lra, respectively).
11_,4 Directly Induces IL.Ira Gene Expression and Peptide Secretion.
Since monocytes obtained from patients on II,-4 therapy expressed substantially augmented gene expression for I1: lra, we examined I1:4 regulation of monocyte I1:lra in vitro. Elutriated monocytes from normal individuals were incubated with varying concentrations of I1:4 for 4 h at 37~ As can be seen in Fig. 3 A, II.-4 induced detectable gene expression for IL, lra at concentrations as low as 0.1 ng/ml (Genzyme Corp.) or 10 U/ml (Immunex Corp.), which increased with higher concentrations of I1:4. When the I1-4 was preincubated with a rabbit polyclonal neutralizing antibody to I1:4 (Genzyme Corp.), the I1:4-induced increase in monocyte expression of I1:lra transcripts was significantly inhibited (data not shown).
To establish whether the I1:4-induced I1:lra gene expression was accompanied by IL-lra secretion, monocytes were cultured with or without increasing concentrations of I1:4 for 12-24 h. The supernatants were harvested and I1:lra was assayed in the supernatants by ELISA. IL-4 caused a dosedependent increase in the amount of IL-lra detected in the culture supernatants which plateaued at 12 h (Fig. 3B ).
DifferentiaI Regulation of lLlra and II_,I mRNA. Although monocytes exposed to Ib4 in vivo or cultured with II:4 in vitro demonstrate increased expression of IL-lra mKNA, no Ib13 mRNA could be detected ( Fig. 1 and Fig. 4 ) indicating independent and selective regulation of I1:lra. In the presence of LPS, which induces both II-1 and I1:lra (24, Fig.  4 ), I1:4 differentially regulates these two members of the I1:1 family. While augmenting IL-lra mRNA expression, IL,4 dramatically suppresses LPS-induced I1:1/~ mRNA (Fig. 4) . The net effect of these actions of I1:4 is to neutralize I1:1, both by inhibiting IL-1 production and promoting synthesis and secretion of its antagonist.
Kinetics oflLIra Expression. Based on the ability of I1:4
to independently induce only the I1:lra member of the I1:1 family, we further explored the mechanism of I1:lra regulation. The kinetics associated with the Ib4-induced expression of IL-lra mRNA were determined by culturing elutriated monocytes in the absence or presence of I1:4 (1 ng/ml) for 30 min up to 24 h. Total cellular RNA was isolated and by Northern analysis, monocytes exposed to I1:4 exhibited a time-dependent increase in the level of I1:lra gene expression with peak levels evident within 2-4 h (Fig. 5) . Increased expression was transient as mRNA levels subsided and returned to near baseline by 24 h. Densitometric analysis of the I1:lra signals reflected this increase in transcripts which plateaued within 2-4 h and subsequently declined (Fig. 5) .
Regulation of lL1ra mRNA by 11.,4. To investigate potential molecular mechanisms whereby I1:4 induces increased I1:lra transcripts, the influence of I1:4 on stability of transcribed mRNA was examined. After a 4-h incubation with II:4 (1 ng/ml), actinomycin D (5/zg/ml), an inhibitor of mRNA transcription, was added to the cultures and at increasing intervals, the cultures were processed for Northern analysis. As shown in Fig. 6 A, the I1:4-induced increase in I1:lra mRNA (fivefold) demonstrated a time-dependent decrease after the addition of actinomycin D, reflecting RNA degradation. Although control (non-Ib4 treated) monocytes formation, prevents protein synthesis. Although the addition of Cx (0.5 or 1.0 #g/ml) did not augment Iblra mRNA in the absence of II-4, the inclusion of Cx with Ib4 increased expression of I1,1ra mRNA two-to threefold above the levels observed for II-4 alone (Fig 6 B) . According to these data, a short-lived or labile protein may be involved in the regulation of I1-1ra expression.
To document a transcriptional regulation of I1-1ra by I1-4, nuclear runoff experiments were performed in which nuclei from monocytes cultured with either medium alone or I1-4 were allowed to synthesize mRNA for a defined period of time in vitro. The resulting transcripts were then hybridized to cDNA probes (pGEM vector control, I1-1ra, and GAPDH) generally do not constitutively express detectable steady-state levels of I1,1ra mlLNA, occasional donor cells were positive for I1,1ra transcripts. To compare the message stability in the absence and presence of I1,4, the data represented in Fig. 6 are from a donor with low, but detectable levels of uninduced I1,1ra mlLNA. No differences were observed in the half-life of the mRNA irrespective of the addition of I1,4. When the mRNA bands were analyzed densitometrically and the resulting values plotted vs time, the approximate half-life of Iblra calculated from the decay curves was 2.5-3 h (Fig. 6  A) . These data suggest that I1.-4 does not increase the amount of Iblra mRNA only through a stabilization of the mRNA molecule.
Iblra gene expression was further examined in the presence of cycloheximide (Cx) which, by inhibiting peptide bond were cultured in the presence or absence of IL-4 (10 ng/ml) for 4 h, nuclei were isolated and a nuclear runoff assay performed, pGEM cDNA served as a vector control, whereas GAPDH cDNA served as a housekeeping control. fixed on nitrocellulose filters. A threefold increase in the amount of synthesized transcripts for ILlra occurred after monocytes had been cultured with IL-4 ( Fig. 6 C) , consistent with a direct effect of IL-4 on the rate of transcription.
Discussion
Originally defined by its ability to promote B cell growth and IgE synthesis, continuing exploration of the role of IL-4 in host defense has revealed its significant ability to suppress numerous mononuclear phagocyte functions (6-10) and promote programmed cell death (25) . In this study, we define yet another mechanism whereby Ib4 may suppress the immune response as shown in cancer patients receiving IL-4 therapy. In these patients, we demonstrate that systemically administered IL-4 sdectively induces transcription and translation of IL-lra, a competitive inhibitor of the multifunctional cytokine, IL-1. Induced circulating levels of IL-lra may provide an immunosuppressive signal not inconsistent with the lack of augmented tumoricidal activity observed in these patients (26) . Although LPS (24) , TGF-B (27, 28) , and GM-CSF (24, 29) also induce IL-lra, each of these mediators also induces variable amounts of IL-1. As shown here and in recent studies (14, 30 ), 1D4 appears unique in its ability to selectively induce IL-lra in resting monocytes without affecting IL-1, whereas in monocytes stimulated by LPS (15, 16, 30 , and Fig. 4) or TGF-fl (Wahl, S., G. Costa, H. Wong, and M. Brandes, manuscript submitted for publication), IL-4 not only augments IL-lra, but it dramatically inhibits IL1B expression. In the tumor patients receiving exogenous IL-4, a number of compromised monocyte functions have been ascribed to IL-4 coincident with the increased expression of IL-lra (7), which document its immunosuppressive potential. Moreover, elevated endogenous levels of II.-4, as occur in visceral leishmaniasis (31) , are also reflected by suppressed monocyte functions and defects in cell-mediated immunity.
There are several possible mechanisms whereby IL-4 may influence Iblra gene transcription and monocyte function. The Ib4-induced accumulation of IL-lra message appeared not to be due only to a decreased rate of degradation, and by performing nuclear runoff experiments, Ib4 was shown to induce an increase in the rate of transcription. Furthermore, the ability of Cx to superinduce IL-4-mediated IL-lra mRNA suggests that a regulatory protein may exist to repress transcription, possibly by interacting with a negative regulatory element in the promoter region of the Iblra gene (32) . Although the region that is located 294 bp proximal of the promoter contains the critical sequences necessary for regulated expression of IL-lra transcripts, it is unlikely that a putative labile protein repressor acts directly at the transcriptional level since Cx does not affect the production of IL-lra mRNA in the absence of Ib4. It is conceivable that Ib4 interacts directly with a labile cytosolic regulatory molecule, and a depletion of this molecule may modulate IL-4 effects on the cell. Dissecting these pathways is crucial to defining the reciprocal effects of IL-4 on IL-13 and IIr By competitively blocking Ibl binding to the IL-1R and lacking any agonist effect, IL-lra exerts a variety of antiinflammatory activities. For example, IL-l-mediated leukocyte adhesion to vascular endothdium is blocked by IL-lra (33) . The antagonist also reverses IL-l-induced production of PGE2 and collagenase by fibroblasts, synoviocytes, and chondrocytes in culture (34, 35) . Moreover, as an inhibitor of Ibl-induced degradation of proteoglycans and of glycosaminoglycan synthesis in cartilage explants (36) , Iblra has been proffered as a potential therapeutic agent for arthritic lesions. Taking these in vitro observations a step further, ILlra has been administered in vivo and found to block Ibl-induced accumulation of leukocytes in inflamed joints (37, 38) , and to reduce proteoglycan release from articular cartilage (37) . The demonstrated ability of IL, lra to ameliorate arthritis in both the type II collagen model (39) and the bacterial cell wall model (40) has prompted clinical trials of this antagonist in rheumatoid arthritis (41) .
Although IL-lra is an important antiinflammatory agent, IL-4, which not only induces IL-lra production, but also has numerous additional antiinflammatory effects, may prove a more effective inhibitor of chronic or aberrant immune function. In this regard, recent studies in bacterial cell wall-induced arthritis have documented that systemic administration of I1.-4 does, in fact, increase expression of Iblra in the arthritic animals with a concomitant decrease in monocyte-macrophage functions, and suppression of joint swelling and tissue destruction (42; Allen, J., H. Wong, G. Costa, M. Bienkowski, and S. Wahl, manuscript submitted for publication). These observations are consistent with the induction of IL-lra in cancer patients receiving exogenous II~4 therapy in this study, and suggest that the use of systemically administered II:4 may have important clinical significance as an antiinflammatory agent, especially in chronic inflammatory disease. Parenthetically, although no demonstrable antitumor effects were observed in the cancer patients treated with IL4 alone (26) , one patient with a chronic psoriatic condition improved clinically during the course of IL-4 treatment (Lotze, M., unpublished observation). Through the induction of IL-lra and its emerging spectrum of monocyte inhibitory activities, IL-4 may prove to have important clinical applications.
